Get the Stockscreener App
22.09
0.41%
-0.09
Pre-market:
22.09
Acadia Pharmaceuticals Inc stock is traded at $22.09, with a volume of 2.02M.
It is down -0.41% in the last 24 hours and up +0.32% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
See More
Previous Close:
$22.18
Open:
$22.25
24h Volume:
2.02M
Relative Volume:
1.09
Market Cap:
$3.78B
Revenue:
$1.10B
Net Income/Loss:
$375.65M
P/E Ratio:
10.06
EPS:
2.1963
Net Cash Flow:
$113.59M
1W Performance:
-2.08%
1M Performance:
+0.32%
6M Performance:
-8.03%
1Y Performance:
+28.73%
1-Day Range:
$21.88
$22.39
1-Week Range:
$21.41
$22.91
52-Week Range:
$16.97
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.09 | 3.80B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Upgrade | Mizuho | Neutral → Outperform |
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Acadia Pharmaceuticals (ACAD) CEO Highlights Global R&D Partners - GuruFocus
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Biopharmas look to China, elsewhere for partnerships, R&D (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady - Investing.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
ACAD Q1 earnings & revenues miss estimates despite Y/Y sales growth - MSN
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms - sharewise.com
ACADIA Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - 富途牛牛
Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts - Yahoo Finance
(ACAD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Acadia launches powder version of Rett syndrome treatment in the US - MSN
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback - Sahm
Acadia reaffirms 2026 total revenue guidance of $1.22B-$1.28B as remlifanserin Phase II ADP readout nears - MSN
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns - Sahm
What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Lowered to $32 - GuruFocus
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution - AD HOC NEWS
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call - TipRanks
ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights – DAYBUE and NUPLAZID UpdateNews and Statistics - IndexBox
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained - TipRanks
H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast By Investing.com - Investing.com South Africa
Is ACADIA Pharmaceuticals (ACAD) Offering Value After A 45% One Year Share Price Gain? - simplywall.st
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth - The Globe and Mail
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com UK
Acadia Pharmaceuticals Q1 2026 Financial Results: DAYBUE and NUPLAZID Sales Growth, Reaffirms Full Year Guidance - Minichart
Acadia (ACAD) Q1 2026 Earnings Transcript - AOL.com
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance - BioSpace
ACADIA Pharmaceuticals Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ACAD) 2026-05-06 - Seeking Alpha
ACADIA (NASDAQ: ACAD) posts Q1 2026 sales gains but lower profit - Stock Titan
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast - Investing.com Nigeria
ACADIA Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
MSN Money - MSN
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates - Yahoo Finance
Earnings Scheduled For May 6, 2026 - Benzinga
Acadia (NASDAQ: ACAD) reaffirms 2026 outlook after Q1 results - Stock Titan
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower - ChartMill
ACADIA PHARMACEUTICALS ($ACAD) Releases Q1 2026 Earnings - Quiver Quantitative
Acadia: Q1 Earnings Snapshot - WKYC
Acadia posts $268M quarter as Alzheimer’s study nears fall data - Stock Titan
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? - Investing.com Australia
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):